Follow-up | |||||
---|---|---|---|---|---|
Admission | 2 weeks | 3 months | 6 months | 1 year | |
Visit | Xa | X | X | X | X |
Informed consent | Xa | ||||
Baseline clinical characteristics | Xa | ||||
Blood analyses | Xa | X | X | X | X |
Magnetic resonance imaging | Xa | X | |||
Computed tomography | Xa | ||||
Plain radiographs | Xa | X | X | ||
Neurological assessment including the ASIA motor score and ASIA impairment scale | Xa | X | X | X | X |
Evaluation of adverse events | |||||
SCIM version 3 | X | X | X | X | |
WISCI II | X | X | |||
SF-36 | X | X | |||
EQ-5D | X | X | X | X | |
NPSI | X | X |